These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37268805)

  • 1. BRAF Mutations in CNS Tumors-Prognostic Markers and Therapeutic Targets.
    Muniz TP; Mason WP
    CNS Drugs; 2023 Jul; 37(7):587-598. PubMed ID: 37268805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canadian Consensus for Treatment of BRAF
    Erker C; Vanan MI; Larouche V; Nobre L; Cacciotti C; Vairy S; Zelcer S; Fleming A; Bouffet E; Jabado N; Legault G; Renzi S; McKeown T; Crooks B; Thacker N; Ramaswamy V; Coltin H; Lafay-Cousin L; Cheng S; Hukin J; Climans SA; Lim-Fat MJ; McKillop S; Lapointe S; Alves M; Bennett J; Tabori U; Perreault S
    Curr Oncol; 2024 Jul; 31(7):4022-4029. PubMed ID: 39057171
    [No Abstract]   [Full Text] [Related]  

  • 3. BRAF-Targeted Therapy in the Treatment of
    Johanns TM; Ansstas G; Dahiya S
    J Natl Compr Canc Netw; 2018 Apr; 16(4):451-454. PubMed ID: 29632063
    [No Abstract]   [Full Text] [Related]  

  • 4. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
    Klempner SJ; Gershenhorn B; Tran P; Lee TK; Erlander MG; Gowen K; Schrock AB; Morosini D; Ross JS; Miller VA; Stephens PJ; Ou SH; Ali SM
    Cancer Discov; 2016 Jun; 6(6):594-600. PubMed ID: 27048246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Role of BRAF Mutation in Low-Grade Gliomas: Meta-analysis.
    Kai Z; Dingyang L; Zhuanyi Y
    World Neurosurg; 2021 Mar; 147():42-46. PubMed ID: 33316486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using BRAF(V600E) as a marker of autophagy dependence in pediatric brain tumors.
    Mulcahy Levy JM; Foreman NK; Thorburn A
    Autophagy; 2014; 10(11):2077-8. PubMed ID: 25484091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors.
    Preusser M; Bienkowski M; Birner P
    Expert Opin Investig Drugs; 2016; 25(1):7-14. PubMed ID: 26536389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MR Imaging of Pediatric Low-Grade Gliomas: Pretherapeutic Differentiation of
    Trasolini A; Erker C; Cheng S; Crowell C; McFadden K; Moineddin R; Sargent MA; Mata-Mbemba D
    AJNR Am J Neuroradiol; 2022 Aug; 43(8):1196-1201. PubMed ID: 35863783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.
    Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T
    Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To BRAF or not to BRAF: is that even a question anymore?
    Horbinski C
    J Neuropathol Exp Neurol; 2013 Jan; 72(1):2-7. PubMed ID: 23242278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF Inhibition in
    Kaley T; Touat M; Subbiah V; Hollebecque A; Rodon J; Lockhart AC; Keedy V; Bielle F; Hofheinz RD; Joly F; Blay JY; Chau I; Puzanov I; Raje NS; Wolf J; DeAngelis LM; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
    J Clin Oncol; 2018 Dec; 36(35):3477-3484. PubMed ID: 30351999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.
    Sasame J; Ikegaya N; Kawazu M; Natsumeda M; Hayashi T; Isoda M; Satomi K; Tomiyama A; Oshima A; Honma H; Miyake Y; Takabayashi K; Nakamura T; Ueno T; Matsushita Y; Iwashita H; Kanemaru Y; Murata H; Ryo A; Terashima K; Yamanaka S; Fujii Y; Mano H; Komori T; Ichimura K; Cahill DP; Wakimoto H; Yamamoto T; Tateishi K
    Clin Cancer Res; 2022 Jun; 28(11):2425-2439. PubMed ID: 35344043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
    Lassaletta A; Zapotocky M; Mistry M; Ramaswamy V; Honnorat M; Krishnatry R; Guerreiro Stucklin A; Zhukova N; Arnoldo A; Ryall S; Ling C; McKeown T; Loukides J; Cruz O; de Torres C; Ho CY; Packer RJ; Tatevossian R; Qaddoumi I; Harreld JH; Dalton JD; Mulcahy-Levy J; Foreman N; Karajannis MA; Wang S; Snuderl M; Nageswara Rao A; Giannini C; Kieran M; Ligon KL; Garre ML; Nozza P; Mascelli S; Raso A; Mueller S; Nicolaides T; Silva K; Perbet R; Vasiljevic A; Faure Conter C; Frappaz D; Leary S; Crane C; Chan A; Ng HK; Shi ZF; Mao Y; Finch E; Eisenstat D; Wilson B; Carret AS; Hauser P; Sumerauer D; Krskova L; Larouche V; Fleming A; Zelcer S; Jabado N; Rutka JT; Dirks P; Taylor MD; Chen S; Bartels U; Huang A; Ellison DW; Bouffet E; Hawkins C; Tabori U
    J Clin Oncol; 2017 Sep; 35(25):2934-2941. PubMed ID: 28727518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
    Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
    Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF Mutation is Associated with an Improved Survival in Glioma-a Systematic Review and Meta-analysis.
    Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Fung KM; Hassell L
    Mol Neurobiol; 2018 May; 55(5):3718-3724. PubMed ID: 28534272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical review of RAF inhibitors in BRAF-mutated glioma treatment.
    Khoury JE; Wehbe S; Attieh F; Boutros M; Kesrouani C; Kourie HR
    Pharmacogenomics; 2024; 25(7):343-355. PubMed ID: 38884947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.
    Horbinski C; Nikiforova MN; Hagenkord JM; Hamilton RL; Pollack IF
    Neuro Oncol; 2012 Jun; 14(6):777-89. PubMed ID: 22492957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation.
    Dodgshun AJ; SantaCruz N; Hwang J; Ramkissoon SH; Malkin H; Bergthold G; Manley P; Chi S; MacGregor D; Goumnerova L; Sullivan M; Ligon K; Beroukhim R; Herrington B; Kieran MW; Hansford JR; Bandopadhayay P
    J Neurooncol; 2016 Jun; 128(2):293-302. PubMed ID: 26994902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabrafenib plus trametinib in patients with BRAF
    Wen PY; Stein A; van den Bent M; De Greve J; Wick A; de Vos FYFL; von Bubnoff N; van Linde ME; Lai A; Prager GW; Campone M; Fasolo A; Lopez-Martin JA; Kim TM; Mason WP; Hofheinz RD; Blay JY; Cho DC; Gazzah A; Pouessel D; Yachnin J; Boran A; Burgess P; Ilankumaran P; Gasal E; Subbiah V
    Lancet Oncol; 2022 Jan; 23(1):53-64. PubMed ID: 34838156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
    Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
    Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.